News from Wednesday, September 6, 2023
Articles
Two Value-Based Care Initiatives That Could Shift the Alternative Payment Model Landscape
(9/6, Stephanie Baum, MedCity News) reports “...One focuses on supporting family caregivers of dementia patients to forestall their admission to a nursing home and the considerable costs that accompany that decision. Another makes it easier for small primary care practices with no prior experience to pursue bundled payment plans over a 10-year period. Both are ambitious pilot programs which could have a significant impact on healthcare delivery.” Full
European HTA Network Rejects Industry Criticism Of Joint Clinical Assessments
(9/6, Francesca Bruce, Pink Sheet) reports “...EUnetHTA 21, the EU health technology assessment network that will soon hang up its hat has defended the methodologies it developed to support the EU HTA Regulation in the wake of criticism from industry.” Subscription Required
UK: Bristol Myers Squibb’s Camzyos Gets NICE Recommendation
(9/6, John Pinching, PharmaTimes) reports “...Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence has published final guidance recommending its Camzyos drug for use across the NHS. Also known as mavacamten, the therapy is a first-in-class treatment option among adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).” Full
Press Releases
PCORI Offers up to $610 Million Through New Research Funding Opportunities
(9/6, PCORI Press Release) “...The first Topical PFAs advance PCORI’s funding on two of the 12 Topic Themes approved by its Board of Governors to guide the organization’s funding for several funding cycles...One of the new Topical PFAs concentrates on sleep health with emphasis on high-need or underserved populations such as shift workers and individuals with multiple chronic conditions. The other encompasses an array of clinical questions on cardiovascular disease involving prevention, screening, diagnosis, treatment and post-treatment interventions with special attention to populations experiencing disparities.” Full
Flatiron Health Enters New Five-Year Research Collaboration with FDA on Real-World Data
(9/6, Flatiron Health Press Release) “Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence of the United States Food and Drug Administration to jointly develop and implement specific research projects to advance the use of real-world data and explore the potential strengths and limitations of using real-world evidence for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.” Full
Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated
(9/6, No Patient Left Behind Press Release) “...The report found that the methodology used by the Institute for Clinical and Economic Review for analyzing the cost-effectiveness of drugs has been incorrectly claiming a number of medications offer insufficient value to patients and society. ‘It’s time to get cost-effectiveness math right and stop using flawed math to undervalue the patient and societal benefits of new medicines,’ said Peter Rubin, Executive Director of No Patient Left Behind. ‘This report quantifies how society derives tremendous value from the net prices of new medicines and debunks the math used by insurers and foreign governments to justify that prescribed treatments are not worth covering at low out-of-pocket costs to premium-paying members.’” Full
Journals
Comparative Effectiveness of Hypoglossal Nerve Stimulation and Alternative Treatments for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis
Do Hyun Kim, et al.
September 4, 2023, Journal of Sleep Research
Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy
Jung-Yun Lee, MD, PhD, et al.
September 6, 2023, JAMA Surgery
Reports
Getting the Math Right When Measuring the Value of New Medicines
September 6, 2023